Updated guidelines for immune thrombocytopenic purpura: Expanded management options.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 34857604.
- Also identified by DOI 10.3949/ccjm.88a.20201.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The current American Society of Hematology (ASH) guidelines for the management of patients with immune thrombocytopenic purpura (ITP) are an update to the 2011 guidelines. The updates focus on treating patients with ITP without bleeding in both outpatient and inpatient settings, including those with newly diagnosed, persistent, and chronic ITP refractory to first-line therapy. Recommendations for therapy include corticosteroids, intravenous immunoglobulins, anti-D immunoglobulin, rituximab, splenectomy, and thrombopoietin-receptor agonists, as well as observation.
Medical subject headings
- Purpura, Thrombocytopenic, Idiopathic